The INDIGO trial for vorasidenib used "time to next intervention" as a key secondary endpoint. This patient-centric metric values delaying more toxic treatments like radiation and chemotherapy, thereby preserving neurocognitive function and quality of life, not just measuring tumor progression.
For pediatric low-grade gliomas, carboplatin and vincristine became the standard of care over the more effective TPCV regimen. This decision highlights the critical trade-off in pediatric oncology, where managing toxicity and long-term side effects in children can outweigh achieving maximum efficacy.
The pan-RAF inhibitor tovorafenib causes a significant, but reversible, decrease in growth velocity in children. This is not due to endocrinopathy but direct C-RAF inhibition slowing growth plate maturation. Growth resumes and "catches up" after therapy cessation, a critical counseling point for families.
Unlike most cancers, National Comprehensive Cancer Network (NCCN) guidelines recommend clinical trials as the preferred first-line treatment for glioblastoma patients with good performance status. This rare recommendation highlights the dismal outcomes with existing therapies and the urgent need for therapeutic innovation.
Beyond improving progression-free survival, the targeted therapy vorasidenib also provides a significant quality-of-life benefit by improving seizure control. Seizures are a common presenting symptom for low-grade glioma patients, and this added therapeutic effect makes the drug a more holistic treatment option.
The success of the IDH inhibitor vorasidenib in glioma was driven by its specific design for blood-brain barrier (BBB) penetration. This contrasts with its predecessor, which failed in brain tumors due to poor CNS penetration, highlighting that BBB is a critical design consideration for neuro-oncology drugs.